Company name: Verdemed
Also known as:
Description: Provider of cannabinoid-based pharmaceuticals to doctors and patients in Latin America intended to offer the best of approved cannabinoid products to Latin Americans, in all legal jurisdictions of medical cannabis. The company focuses on existing product formulations of cannabinoid pharmaceuticals and offers cannabinoid-based medications approved by the main regulatory agencies in the region, enabling doctors to improve the treatment of patients.
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Start up capital raised (USD Million): 5.00
Business status: Generating Revenue
Ownership: Privately Held (no backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Earnings before interest, tax, depreciation and amortization (EBITDA):
Financing Status: The company entered into a definitive agreement to receive US$ 5 million of development capital from Brazilian and Colombian investor on October 2, 2018.
Number of active investors:
Profile last updated: 08-Oct-2018
Last known valuation:
Last known valuation date: